Surrozen EBITDA 2021-2024 | SRZN

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Surrozen ebitda from 2021 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Surrozen ebitda from 2021 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$95B
Zoetis (ZTS)	$66.3B
Takeda Pharmaceutical (TAK)	$46.8B
Daiichi Sankyo, - (DSNKY)	$41.7B
Summit Therapeutics (SMMT)	$18.2B
Sandoz Group AG (SDZNY)	$17.7B
Merck (MKKGY)	$17.2B
Astellas Pharma (ALPMY)	$16.9B
Shionogi (SGIOY)	$14.1B
United Therapeutics (UTHR)	$12.8B
Neurocrine Biosciences (NBIX)	$10B
IPSEN (IPSEY)	$8.6B
Orion OYJ (ORINY)	$8B
Madrigal Pharmaceuticals (MDGL)	$6.7B
Stevanato Group S.p.A (STVN)	$6.6B
Corcept Therapeutics (CORT)	$6.6B
Hikma Pharmaceuticals Plc (HKMPF)	$5.8B
Ono Pharmaceutical (OPHLF)	$5.5B
Grifols, S.A (GRFS)	$4.9B
Ionis Pharmaceuticals (IONS)	$4.5B
Soleno Therapeutics (SLNO)	$3.2B
Crinetics Pharmaceuticals (CRNX)	$2.8B
Catalyst Pharmaceuticals (CPRX)	$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.3B
Recursion Pharmaceuticals (RXRX)	$2.2B
Hypermarcas (HYPMY)	$2.1B
NewAmsterdam Pharma (NAMS)	$1.8B
Centessa Pharmaceuticals (CNTA)	$1.6B
BioCryst Pharmaceuticals (BCRX)	$1.5B
Guardian Pharmacy Services (GRDN)	$1.5B